CClinicalTrials.gg
CompletedNCT02084472Updated Mar 12, 2014

Accessible and Affordable Moisturizers for Atopic Eczema

An interventional study of Baby oil and petroleum jelly in Childhood Atopic Dermatitis, sponsored by Red Cross War Memorial Childrens Hospital. Completed at 1 site in South Africa. Open to participants aged 6 Months to 12 Years. Per ClinicalTrials.gov, last updated 2014-03-12.

Sponsored by Red Cross War Memorial Childrens Hospital · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
6 Months to 12 Years
Sex
All
01

Study summary

Aqueous (EUA) cream, cetomacrogol (CMG) and emulsifying ointment (HEB) are in South Africa's essential drug list (EDL) but are not available to most rural patients. To assess whether accessible moisturizers can be used as alternatives in atopic eczema (AD), a randomized controlled trial of patients with mild-to-moderate AD, aged 1-12 years was conducted. Two separate sub-studies were conducted using a randomized controlled single (assessor) blind trial design. Study 1 compared UEA vs. liquid paraffin (unscented baby oil) for baths, all patients used HEB as moisturiser. In Study 2, 4 moisturisers were compared -HEB, CMG, petroleum jelly and petroleum jelly/Glycerine (2:1). Assessments (SCORAD, POEM, NESS and IQDOL) carried out at baseline, week 4, 8 and 12. Routine topical steroids and antihistamines were continued as prescribed.

02

Conditions studied

  • Childhood Atopic Dermatitis

Keywords

  • atopic eczema
  • moisturisers
  • alternatives
  • affordable
03

In context

Dermatitis, Atopic

1,419 studies on the registry are indexed under Dermatitis, Atopic; 258 are open to participants now.

This study's enrollment of 120 is above the median of 83 across 1,125 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Red Cross War Memorial Childrens Hospital is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with Atopic dermatitis as defined by the united kingdom (UK) Working party Diagnostic Criteria
  • Atopic Dermatitis patient with mild to moderate stable atopic eczema with parents/guardians willing and able to apply study moisturizers as directed and commit to attend all visits.

Exclusion criteria

Exclusion Criteria:

  • Less than 1 year of age
  • Patients with atopic dermatitis treated with systemic preparations
05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    study 1: aqueous cream and baby oil

    enrolled patients in this arm use either aqueous cream or baby oil as a soap substitute

    Other: Baby oil

  • Active comparator
    study 2: emulsifying ointment and cetomacrogol

    patients in this study arm continue to use emulsifying ointment and cetomacrogol as a moisturiser, the current standard of care in our institution

    Other: petroleum jelly · Other: Glycerine:petroleum jelly 2:1

Interventions

  • OtherBaby oil

    patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream

    Also known as: unscented liquid paraffin

  • Otherpetroleum jelly

    patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser

  • OtherGlycerine:petroleum jelly 2:1

    patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser

06

What researchers measure

Primary outcomes

  1. Change in the validated SCORing Atopic Dermatitis(SCORAD)

    Change in the validated SCORing Atopic Dermatitis(SCORAD) and two other validated clinical scores (Nottingham Atopic Eczema Severity Score(NESS) and Patient Oriented Eczema Measure(POEM) were used to measure the extent/severity of AD. A validated quality-of-life form using the infants dermatitis quality of life (IDQOL) scale was completed by each care-giver at each visit.

    Time frame: Baseline, week 4, 8 and week 12

Secondary outcomes

  1. Change in the patient quality-of-life as measured by the infants dermatitis quality of life (IDQOL) index at each visit.

    Time frame: Baseline, week 4, 8,12

07

Study locations

1 site
  • Red Cross War Memorial Children's Hospital
    Cape Town, Western Cape 7700, South Africa
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02084472
Lead sponsor
Red Cross War Memorial Childrens Hospital
Responsible party
Dr Carol Hlela (Dermatologist, Red Cross War Memorial Childrens Hospital) — Principal investigator
First posted
Mar 12, 2014
Start date
Feb 2013
Primary completion
May 2013
Completion
Jul 2013
Last update
Mar 12, 2014

Study contacts

Nonhlanhla Khumalo, MD, PhD
study director · University of Cape Town
Carol Hlela, MD, PhD
principal investigator · Red Cross War Memorial Children's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion